SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
EU to Propose New Rules Limiting Children's Access to Social Media 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Smithsonian Rejects White House Claims of ‘Anti-American’ Bias 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Super Micro Employees Detained in Taiwan AI Server Export Investigation 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
USA at 250: the Black American struggle for life, liberty and the pursuit of happiness 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Vietnam’s population hit the 100 million milestone. Where’s it headed? 
Vanda Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its drug tradipitant, branded as Nereus, marking the first new FDA-approved treatment for motion-induced vomiting in more than 40 years. The company announced that it plans to launch the drug in the United States in the coming months, a move that could significantly change the treatment landscape for motion sickness.
Motion-induced vomiting, often referred to as motion sickness, occurs when the brain receives conflicting signals from the eyes, inner ear, and body sensors. This condition commonly affects people during travel activities such as boating, driving, or flying and has long relied on older treatment options with limited innovation.
The FDA’s approval of Nereus was supported by two late-stage clinical trials involving a total of 681 patients. Results from these studies showed that tradipitant significantly reduced episodes of vomiting compared to placebo. The drug works by blocking a specific brain receptor associated with nausea and vomiting, offering a targeted and modern approach to treatment.
According to H.C. Wainwright analyst Raghuram Selvaraju, peak annual sales of tradipitant for motion sickness alone could exceed $100 million in the U.S., highlighting its strong commercial potential. Currently available motion sickness treatments include Viatris’ scopolamine patch Transderm Scop, WellSpring Pharmaceutical’s Bonine, and Prestige Consumer Healthcare’s Dramamine, many of which have been on the market for decades.
Tradipitant’s regulatory journey faced challenges in the past. In December 2018, the FDA placed a partial clinical hold on the drug, requesting additional long-term toxicity studies in dogs after classifying motion sickness as a chronic condition. However, the agency reversed its stance, reclassifying motion sickness as an acute condition and lifting the clinical hold on December 4, eliminating the need for further studies.
Vanda licensed tradipitant from Eli Lilly in 2012 and continues to study the drug for multiple indications, including gastroparesis and nausea linked to certain diabetes medications. The company has not yet disclosed pricing details for Nereus.
